D
iphtheria-tetanus toxoid-five-component acellular pertussis (DTaP 5 ), inactivated poliovirus (IPV), and Haemophilus influenzae type b (Hib) (DTaP 5 -IPV-Hib) vaccine (Pediacel; Sanofi Pasteur Limited, Toronto, Ontario, Canada) is a fully liquid combination vaccine for primary and booster vaccination of infants and toddlers against infectious diseases caused by Clostridium tetani, Corynebacterium diphtheriae, Bordetella pertussis, Hib, and poliovirus types 1, 2, and 3. This licensed pentavalent vaccine comprises a 5-component acellular pertussis vaccine, adsorbed diphtheria and tetanus toxoids, inactivated poliomyelitis vaccine (IPV) grown in Vero cells, and a purified polyribosylribitol phosphate (PRP) capsular polysaccharide of Hib conjugated to tetanus toxoid. As a fully liquid formulation, DTaP 5 -IPV-Hib prevents dosing errors that can occur during reconstitution of vaccine components and may be more convenient for health care providers.
The safety and immunogenicity of DTaP 5 -IPV-Hib using 3-dose primary vaccination schedules have previously been demonstrated in clinical studies in infants (1) (2) (3) (4) (5) (6) (7) (8) and toddlers (4, (9) (10) (11) . This is the first study to have evaluated the 3-, 5-, and 12-month schedule employed in some countries, particularly in Europe, and to have compared the safety and immunogenicity of 
MATERIALS AND METHODS
This phase III, randomized, controlled, modified double-blind, multicenter study was conducted at 12 (12) . A modified double-blind design was utilized since the comparator vaccine (DTaP 3 -IPV/Hib) required reconstitution; an unblinded study team member prepared and administered study vaccines but was not involved in data collection. Parents/guardians were kept blinded to the identity of the study vaccine administered. The study complied with the Declaration of Helsinki. The study protocol and informed consent forms were approved by study site ethics committees. The participant parent(s) or legal guardian(s) provided written consent prior to study-specific procedures. The manuscript was prepared according to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals guidelines.
Participants. Participants were eligible for the study if they were 80 to 120 days old and born after a full-term pregnancy (Ͼ37 weeks). Other eligibility requirements can be found at ClinicalTrials.gov (12) .
Vaccines. The administered vaccines were DTaP 5 -IPV-Hib (lot C2314AA) and DTaP 3 -IPV/Hib (lot A20CA124A) (Infanrix-IPVϩHib; GlaxoSmithKline Biologicals, Rixensart, Belgium). DTaP 5 -IPV-Hib contains diphtheria ( 5 -IPV-Hib in each 0.5-ml dose. Vaccines were stored in a temperature-monitored refrigerator at 2°C to 8°C. DTaP 3 -IPV/Hib was reconstituted immediately before administration. No other vaccines were to be coadministered during the study, consistent with country-specific vaccination schedules at the time.
Study design. At study entry, participants were randomly assigned 1:1 to receive DTaP 5 -IPV-Hib (group A) or the control vaccine, DTaP 3 -IPV/ Hib (group B). A single 0.5-ml dose of DTaP 5 -IPV-Hib or DTaP 3 -IPV/ Hib was administered intramuscularly (i.m.) into the anterolateral thigh at 3 months of age (up to 28 days older [ϩ28 days]) and 5 months of age (ϩ28 days) and into the deltoid muscle at 12 months of age (ϩ28 days).
Sera were obtained immediately prior to the first dose of vaccine (dose 1) to evaluate the pertussis antigen seroresponse to PT, FHA, PRN, and FIM; sera were also obtained 28 to 42 days after dose 2 and dose 3 to assess antibody responses to all vaccine antigens.
Endpoints. The primary immunogenicity endpoints were the proportions of participants achieving established long-term seroprotective thresholds with respect to PRP (Ն1.0 g/ml), diphtheria toxoid (Ն0.1 IU/ml), tetanus toxoid (Ն0.1 IU/ml), and poliovirus types 1, 2, and 3 (Ն1:8 dilution). In addition, the proportion of participants achieving seroresponse to pertussis antigens 1 month post-dose 3 was evaluated. Seroresponse was defined as the proportion of participants achieving antibody concentrations Ն the assay lower limit of quantitation (LLOQ) (PT, PRN, and FIM Ն 4 enzyme-linked immunosorbent assay [ELISA] units [EU]/ml; FHA Ն 3 EU/ml) when baseline concentrations were less than the LLOQ or maintenance of baseline antibody concentrations in participants whose values were initially equal to or greater than the LLOQ. Given the lack of an established correlate of protection for pertussis, seroresponse was used to measure vaccine response as levels of maternal antibodies waned.
Secondary immunogenicity endpoints included the proportions of participants achieving established short-term seroprotection thresholds for PRP titers (Ն0.15 g/ml) and diphtheria and tetanus toxoids (Ն0.01 IU/ml) 1 month post-dose 2 (seroprotection rates for poliovirus types 1, 2, and 3 [Ն1:8 dilution] are also presented). For pertussis, the proportion of participants achieving Ն2-fold and Ն4-fold increases in dose 2 and dose 3 pertussis antigen antibody responses from prevaccination levels and dose 2 seroresponse rates were evaluated. Antibody geometric mean concentrations (GMCs) and geometric mean titers (GMTs) against all vaccine antigens after dose 2 and dose 3 were assessed.
Safety endpoints included frequency of solicited injection site reactions (tenderness, erythema, swelling) and solicited systemic reactions (fever, vomiting, abnormal crying, appetite lost, irritability) within 7 days after each vaccination. Solicited reaction intensity criteria are described elsewhere (4) . Additional safety endpoints included frequency of unsolicited adverse events (AEs; reported within 28 days after each injection) and serious AEs (SAEs; reported during the study). Medical Dictionary for Regulatory Activities (MedDRA) version 9.0 terminology was applied to classify AEs. Data quantifying the use of antipyretics or analgesics on days 0 to 7 after vaccination were gathered.
Serologic evaluations. Antibodies to PRP were assessed using a Farrtype radioimmunoassay. Levels of antibodies to diphtheria toxin and poliovirus antigens were measured by seroneutralization assays. Levels of antibodies to tetanus toxoid and pertussis antigens (PT, FHA, PRN, FIM) were assessed by ELISA. These validated assays were performed at Sanofi Pasteur Inc., Swiftwater, PA.
Statistical analysis. The study was powered to test the primary hypotheses in a per-protocol analysis set using the primary endpoints and a prespecified noninferiority margin. The expected seroprotection rates for diphtheria, tetanus, polio and PRP were Ն95%; therefore, a noninferiority margin of 5% was selected. No primary hypothesis was tested for pertussis given the lack of an established correlate of protection and the differing antigen formulations in the study vaccines. With 334 evaluable participants per group, the overall power was approximately 80%. Assuming an attrition rate of 16%, 400 participants per group were to be enrolled.
The primary hypotheses tested whether the proportion of participants achieving post-dose 3 seroprotection levels after DTaP 5 -IPV-Hib vaccination was noninferior to that seen after DTaP 3 -IPV/Hib vaccination. The difference in proportions between group A and group B and the 2-sided 95% confidence interval (CI) based on the Wilson Score method without continuity correction were computed (13) . When the lower limit of the CI was greater than Ϫ0.05 for PRP, diphtheria, tetanus, and all poliovirus antigens, DTaP 5 -IPV-Hib was considered noninferior to DTaP 3 -IPV/Hib. The proportions of participants achieving a pertussis seroresponse post-dose 3 were provided for each group, with 2-sided 95% CIs calculated by the exact method using the F-distribution of Collett (14) .
A secondary hypothesis was that the PRP GMCs after dose 3 of DTaP 5 -IPV-Hib were noninferior to those seen with DTaP 3 -IPV/Hib. The GMC ratio (group A/group B) was calculated, and the associated 2-sided 95% CI was computed by assuming the log normality of concentrations and using the t distribution and the pooled sample variance. If the lower limit of the GMC ratio 95% CI was Ͼ0.67, then the DTaP 5 -IPV-Hib PRP response was considered noninferior to that of DTaP 3 -IPV/Hib. If noninferiority was demonstrated and the lower limit of the 95% CI of the GMC ratio was Ͼ1, then the DTaP 5 -IPV-Hib PRP response was considered superior to the DTaP 3 -IPV/Hib PRP response.
Statistical summaries were provided for each group for secondary endpoints based on the methods described above. Data were analyzed as observed, with no imputation for missing values.
The safety analysis set comprised all participants receiving Ն1 dose of study vaccine and having any safety assessment. The per-protocol analysis set was used for the primary immunogenicity endpoints, including randomized participants who had received the study vaccine as randomized, had a post-dose 3 blood draw within 28 to 42 days, and had no protocol violation potentially affecting primary endpoint immunogenicity assessments. For the immunogenicity endpoints, the full analysis set included all randomized participants who received Ն1 dose of vaccine and pro- vided any blood sample after vaccination. The full analysis set results were consistent with the per-protocol analysis set and are not presented.
RESULTS

Participants.
Randomized participants (n ϭ 807) were allocated to receive DTaP 5 -IPV-Hib (n ϭ 402, group A) and DTaP 3 -IPV/ Hib (n ϭ 405; group B) as shown in Fig. 1 ; 773 participants (95.8%) completed the study. Slightly more participants in group A (5.5%) did not complete the study, largely because of more SAE withdrawals unrelated to vaccination. The safety analysis set comprised 400 (99.5%) participants in group A (2 participants did not report safety data) and 405 (100%) participants in group B; for the per-protocol analysis, 325/402 (80.8%) and 341/405 (84.2%) were included, respectively. For both groups, most protocol violations were for vaccinations given outside the specified time window (Ͼ28 days after the schedule-specified time), blood draws outside the specified time window (Ͼ28 days and Ͻ42 days postvaccination), or no post-dose 3 blood sample drawn: 13.2% (53/402) for group A and 11.1% (45/405) for group B.
Participants were similarly distributed by gender: 221 (55%) males in group A and 211 (52%) males in group B. The median ages in months were 2.9, 4.9, and 12.2 for doses 1, 2, and 3, respectively, and the median ages were the same for both groups. The median body weight of 6.2 kg at study entry was the same in both groups. Immunogenicity. One month post-dose 3 in both groups, the seroprotection rates for PRP, diphtheria and tetanus toxoids, and all poliovirus types were high (Ͼ90%) ( Table 1) . Since the lower bounds of the 95% CI of the differences of the seroprotection rates were greater than the predefined noninferiority margin, group A was noninferior to group B for diphtheria, tetanus, and poliovirus immune responses. For diphtheria, the seroprotection rate for group A was greater than that for group B since the 95% CI of the differences was Ͼ0. For PRP, the seroprotection rate for group A was 93.2% (89.9% to 95.7%) and for group B was 96.8% (94.3% to 98.4%), a difference of Ϫ3.5% (95% CI, Ϫ7.10% to Ϫ0.21%); since the lower bound of the 95% CI of the difference was less than Ϫ0.05, DTaP 5 -IPV-Hib did not meet the noninferiority criteria. Using the Ն0.15 g/ml threshold, the post-dose 3 PRP seropro- tection rate was 99.1% (95% CI, 97.3% to 99.8%) for group A and 99.7% (95%CI: 98.4% to 100%) for group B. The post-dose 2 seroprotection rates for PRP, diphtheria and tetanus toxoids, and polioviruses were similar for each group (Fig. 2) .
Rates of seroresponse to pertussis antigens post-dose 2 and post-dose 3 were high and similar between groups for PT and FHA. The seroresponse rates for PRN were higher post-dose 2 in group B (Table 2 ) but were high (Ն96.9%) and similar post-dose 3 in both groups. FIM seroresponse rates were higher in group A after both doses, as expected, since FIM is not a component of DTaP 3 -IPV/Hib. The proportions of participants achieving Ն2-fold and Ն4-fold seroresponse increases followed a similar pattern, and post-dose 2 and post-dose 3 rates were similar for PT and FHA. PRN rates tended to be higher for group B and FIM rates higher in group A (Table 2) .
Antibody GMCs/GMTs against all antigens in the study vaccines post-dose 2 and post-dose 3 are shown in Table 3 . The GMC ratio (95% CI) of PRP antibodies comparing group A to group B was 0.70 (95% CI, 0.57 to 0.85). Since the lower limit of the 95% CI of the ratio was Ͻ0.67, DTaP 5 -IPV-Hib did not meet the noninferiority criteria for PRP responses. Some numerical differences in the GMCs/GMTs were also observed between groups post-dose 2 and post-dose 3. The values for diphtheria toxoid, PT, and FIM tended to be higher in group A, and those for tetanus, poliovirus, FHA, and PRN tended to be higher in group B. a SR (seroresponse), post-dose 2 or 3 antibody concentration Ն lower limit of quantitation (LLOQ ϭ 4 EU/ml for PT, PRN, and FIM and 3 EU/ml for FHA) when baseline concentrations were ϽLLOQ or at least maintenance of antibody concentration in participants whose values were initially ՆLLOQ; N, number of participants in the per-protocol analysis set; n, number of participants who met the criteria; M, number of participants with at least 1 available per-protocol value; PT, pertussis toxoid; FHA, filamentous hemagglutinin; PRN, pertactin; FIM, fimbria types 2 and 3; CI, confidence interval.
Solicited reactions. Group A and group B exhibited similar rates of solicited injection site and systemic reactions at Յ7 days after vaccination (Fig. 3) . Erythema was the most frequently reported solicited injection site reaction; irritability was the most frequently reported solicited systemic reaction. Most solicited injection site reactions were grade 1 in intensity; reactions occurred and resolved within 1 to 3 days.
Other adverse events. Overall, the proportions of participants reporting unsolicited AEs at Յ28 days postvaccination were similar: 72.5% (95% CI, 67.8% to 76.8%) in group A and 75.8% (95% CI, 71.1% to 79.7%) in group B. The most frequently reported unsolicited AEs in both groups were pyrexia, rhinitis, and otitis media. While the rate of reported SAEs were slightly higher in group A (8.5% [95% CI, 6.0% to 11.7] compared to 5.4% [95% CI, 3.4% to 8.1%] in group B), no SAEs were considered to be vaccination related. The higher rate of SAEs was attributable to the 7 (1.7%) participants who withdrew from the study after an SAE in group A (Fig. 1) ; the reasons for discontinuing included developmental delay (n ϭ 2), mild arrested hydrocephalus (n ϭ 1), congenital atrial septal defect (n ϭ 1), thrombocytopenia (n ϭ 1), diagnosis of epilepsy (n ϭ 1), and an eye disorder (n ϭ 1). All were followed until symptom resolution or the conclusion of the study.
The antipyretic/analgesic use rate 3 days postvaccination ranged from 33.1% to 36.6% in group A and from 24.2% to 44.3% in group B.
DISCUSSION
This study demonstrated that the fully liquid DTaP 5 -IPV-Hib vaccine can be administered using the 3-, 5-, and 12-month vaccination schedule. DTaP 5 -IPV-Hib elicited a robust immune response to all vaccine antigens and had a safety profile similar to that of DTaP 3 -IPV/Hib. DTaP 5 -IPV-Hib was noninferior to DTaP 3 -IPV/Hib as assessed by post-dose 3 rates of seroprotection against diphtheria and tetanus toxoids and poliovirus antigens; the response to diphtheria was found to be higher among DTaP 5 -IPV-Hib recipients. Post-dose 3 PRP seroprotection rates (Ն0.15 g/ml and Ն1.0 g/ml) were high (99.1% and 93.2% after DTaP 5 -IPV-Hib and 99.7% and 96.8% after DTaP 3 -IPV/Hib, respectively); however, predefined noninferiority criteria for DTaP 5 -IPV-Hib were not met for the seroprotection rate at Ն1.0 g/ml or GMCs compared with DTaP 3 -IPV/Hib. Post-dose 2, PRP seroprotection rates (Ն0.15 g/ml) and GMCs also tended to be numerically lower for those receiving DTaP 5 -IPV-Hib. Whether this was due to differences in prevaccination levels is not known since PRP was not assessed at baseline. In contrast, a study conducted in France and Poland (4) found that DTaP 5 -IPV-Hib recipients achieved higher PRP seroprotection rates and GMCs than DTaP 3 -IPV/Hib recipients using a 2-, 3-, and 4-month schedule as well as after the fourth booster dose at 12 to 18 months of age (heptavalent pneumococcal conjugate vaccine [PCV7] was coadministered to both groups). After the 3-dose primary series, PRP seroprotection rates at Ն0.15 g/ml were 91.0% versus 80.8%, at Ն1.0 g/ml were 63.3% versus 38.9%, and GMCs were 1.38 g/ml versus 0.59 g/ml. Post-dose 4, PRP seroprotection rates at Ն1.0 g/ml were 99.1% versus 95.2% and GMCs were 32.4 g/ml versus 19.26 g/ml (4). Similarly, in a German study (9) , 100% of toddlers aged 11 to 18 months (primed with a hexavalent vaccine primary series) who received DTaP 5 -IPV-Hib or DTaP 3 -HBV-IPV/Hib (both coadministered with PCV7) as a fourth booster dose achieved PRP seroprotection rates Ն 1.0 g/ml in both groups; GMCs were higher in those receiving DTaP 5 -IPV-Hib (37.16 g/ml versus 30.27 g/ml for DTaP 3 -HBV-IPV/Hib recipients). In both of these studies, the same laboratory and analysis methods were used as in the current study.
Variability in PRP immune responses is well recognized and may have contributed to the observed differences across studies (15, 16) . Given the clinically similar point estimates, and the high seroprotection rates obtained post-dose 3, it would be difficult to assign much clinical significance to the PRP numerical differences between groups.
Post-dose 2, seroprotection rates elicited against diphtheria, tetanus, and poliovirus type 1 to 3 antigens were similar. For pertussis, the post-dose 2 and 3 PT and FHA seroresponse rates and 2-and 4-fold rise rates were generally similar. For PRN, the postdose 3 rates were high in both groups, although some variability in the immune response after each dose was observed. This was likely due to differences in vaccine antigen content. Rates for FIM were higher in group A as expected since FIM is not a component of the DTaP 3 -IPV/Hib. The lack of a response in group B demonstrates the low background levels of antibody against FIM in the community. Overall, the development of an established correlate of protection for pertussis would assist in the clinical interpretation of pertussis responses.
For the post-dose 2 and 3 GMCs/GMTs, robust immune responses to the vaccine antigens were observed. Numerical differences were observed, but they are unlikely to be clinically relevant given the high seroprotection and seroresponse/fold-rise rates achieved.
One advantage of this study was the ability to directly compare 2 licensed pentavalent pediatric combination vaccines. While differences exist in the composition of the vaccines (e.g., antigen concentrations and aluminum adjuvant), the potential for independent effects and/or interactions of these differences is not clearly apparent. Overall, however, this study did demonstrate robust immune responses after administration of each vaccine.
Compared to a 3-dose primary administration series at 2, 3, and 4 months using the same vaccines (coadministered with PCV7) and laboratory methods (4), 2 doses of vaccine at 3 and 5 months of age (i.e., a 2-dose primary series) tended to elicit lower immune responses (seroprotection rates and GMCs/GMTs). However, a third booster dose administered to participants at 12 months of age resulted in seroprotection rates similar to those seen after a fourth booster dose was administered at 12 to 18 months of age, even though GMCs/GMTs tended to be higher after 4 vaccine doses (4). Still, with both schedules, high seroprotection rates for most antigens were achieved at established levels for the primary and booster series.
Similar safety profiles were observed in both study groups, and there were no unexpected safety issues identified. Although there were a higher number of participants reporting SAEs among those receiving DTaP 5 -IPV-Hib, no SAEs were considered vaccination related. Adverse reactions were generally mild (grade 1 intensity) and of short duration (Յ3 days).
One potential study limitation was the challenge for participants to meet the study windows defined for vaccinations and blood sampling. A total of 70% of 141 protocol violations resulted from nonadherence to such issues (including lack of a post-dose 3 blood draw), but these were distributed similarly in the two study groups. Results from the full analysis set (not shown) confirmed the per-protocol findings.
Overall, the safety and immunogenicity data from this study support DTaP 5 -IPV-Hib administration to infants and toddlers using the 3-, 5-, and 12-month schedule. DTaP 5 -IPV-Hib was shown to elicit a robust immune response and had a safety profile similar to the DTaP 3 -IPV/Hib safety profile. While some numerical differences were observed in the immune responses post-dose 3 between vaccines, clinical significance is unlikely given the high seroprotection and seroresponse rates achieved in both groups.
